Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
Clin Mol Hepatol 2025;31(2):509-524. Published online January 2, 2025
Background/Aims Hepatocellular carcinoma (HCC) exhibits significant sex disparities in incidence, yet its molecular mechanisms remain unclear. We explored the role of telomerase reverse transcriptase (TERT) genetic alterations and hepatitis B virus (HBV) integration, both known major contributors to HCC, in sex-specific risk for HBV-related HCC.
Methods We examined 310 HBV-related HCC tissues to investigate sex-specific TERT promoter (TERT-pro) mutations and HBV integration profiles, stratified by sex and age, and validated with single-cell RNA sequencing (scRNA-seq) data.
Results Tumors predominantly exhibited TERT-pro mutations (26.0% vs. 0%) and HBV-TERT integration (37.0% vs. 3.0%) compared to non-tumorous tissues. While TERT-pro mutations increased with age in both sexes, younger males (≤60 years) showed marked predominance compared to younger females. Males had significantly more HBV integrations at younger ages, while females initially had fewer integrations that gradually increased with age. Younger males' integrations showed significantly greater enrichment in the TERT locus compared to younger females, alongside a preference for promoters, PreS/S regions, and CpG islands. Overall, TERT genetic alterations were significantly sex-differential in younger individuals (75.3% in males vs. 23.1% in females) but not in older individuals (76.9% vs. 83.3%, respectively). These alterations were associated with increased TERT expression. The skewed TERT abnormalities in younger males were further corroborated by independent scRNA-seq data.
Conclusions Our findings highlight the critical role of TERT alterations and HBV integration patterns in the male predominance of HCC incidence among younger HBV carriers, offering insights for future exploration to optimize sex-specific patient care and HCC surveillance strategies.
Citations
Citations to this article as recorded by
Molecular biomarkers and nano-immunopharmacology in inflammatory carcinoma: Bridging mechanisms and therapeutic translation Kamlesh Sahu, Trilochan Satapathy, Poonam Sahu, Om Chandrakar Advances in Biomarker Sciences and Technology.2026; 8: 151. CrossRef
Mutational patterns and ancestry-linked profiles in a large hepatocellular carcinoma and combined hepatocellular–cholangiocarcinoma cohort C. Gerdes, S. Rengarajan, K. Murugesan, J.S. Ross, S. Bartels, A. Vogel, A. Saborowski ESMO Open.2026; 11(2): 106048. CrossRef
Shelterin Component TPP1 Drives Tumor Progression and Predicts Poor Prognosis in Hepatocellular Carcinoma Jung Eun Jang, Hye Seon Kim, Jin Seoub Kim, Jae Mo Han, Hee Sun Cho, Kwon Yong Tak, Ji Won Han, Pil Soo Sung, Si Hyun Bae, Jeong Won Jang Biomedicines.2026; 14(2): 364. CrossRef
Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G. Duda, Ao Huang, Jian Zhou Portal Hypertension & Cirrhosis.2026; 5(1): 65. CrossRef
Digital polymerase chain reaction detection of telomerase reverse transcriptase promoter mutations in hepatitis B virus related hepatocellular carcinoma Shuai Shao, Yu Xiong, Mo-Wei Kong, Yang Yu, Chun-Xiang Zhang World Journal of Gastrointestinal Oncology.2026;[Epub] CrossRef
Clinicopathological significance of Gli1 expression in hepatocellular carcinoma: a meta-analysis Sisi Li, Mengfan Chen, Shanshan Zhang, Zhong Xu, Hongling Wang Scientific Reports.2026;[Epub] CrossRef
Letter to the editor on “Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity” Qicong Mai, Jianming Zheng, Meishi Tang, Yubin Liu Clinical and Molecular Hepatology.2026; 32(2): e134. CrossRef
Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications Wen Kang, Yu-Shen Liu, Tian-Ping Wang, Shu-Ming Zhang, Yu Li, Ye Zhang iLIVER.2026; 5(2): 100235. CrossRef
Association of TERT promoter mutations with early recurrence in hepatocellular carcinoma: a subgroup analysis in a Vietnamese cohort Hanh Thi Tuyet Ngo, Duy Duc Nguyen, Hoang Anh Vu, Thao Thi Phuong Doan, Minh-Xuan Dang, Phat Thi Hong Ho, Khoa Anh Luong BMC Cancer.2026;[Epub] CrossRef
Sex Hormone Receptors, HBV Integrations and Their Prognostic Predictive Value Among Hepatocellular Carcinoma Patients Die He, Xi Zeng, Lei Yin, Yang Liu, Weiping Zhou, Xing Liu, Linghao Zhao International Journal of Cancer.2026;[Epub] CrossRef
Transcriptional regulation of tumor suppressor gene RASSF1A by HBx Yanhong Kang, Wei Li, Junfeng Wei, Lin Yang, Yi Kang Molecular and Cellular Probes.2025; 82: 102034. CrossRef
Optimized digital polymerase chain reaction enables detection of telomerase reverse transcriptase C228T mutation for prognostic assessment in hepatocellular carcinoma Zulihumaer Aizimuaji, Nan Hu, Hai-Yang Li, Xi-Jun Wang, Sheng Ma, Ya-Ru Wang, Rui-Qi Zheng, Zhuo Li, Huan Zhao, Wei-Qi Rong, Ting Xiao World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
First
Prev
